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ABSTRACT 
 
The metabolic syndrome has recently become one of the major public health 
challenges and results from the increasing prevalence of obesity. Erectile dysfunction 
(ED) affects up to half of men over the age of forty. Men with co-morbid disease and 
risk factors including cardiovascular disease, hypertension, dyslipidaemia and 
depression all report a higher prevalence of ED. The current study investigated the 
prevalence of the metabolic syndrome in one hundred men with (ED) presenting to 
the Male Sexual Dysfunction Clinic at the Johannesburg Hospital. 
 
Participants underwent a thorough history taking and examination session which 
included the International Index of Erectile Function Score. Several fasting 
biochemistry and hormonal tests were performed. Participants were divided by race 
into three groups. Data was recorded in EXCEL and reported as mean±std or as a 
number (frequency). Where applicable, correlation between variables was 
determined.  
 
The prevalence of the metabolic syndrome was 39%, with the highest prevalence 
(54%) in the group comprising Asian, Coloured and Chinese participants. Eighty 
percent of participants had moderate-severe (ED), with a mean duration of 3,8 years. 
Glucose and HbA1c were strong predictors of ED duration. Severity of ED was not 
influenced by the presence of the metabolic syndrome. Men presenting with ED may 
represent an ideal patient group to screen for the metabolic syndrome, and therefore 
for cardiovascular disease, especially for those men within the asymptomatic period. 
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CHAPTER ONE 
INTRODUCTION, REVIEW OF THE LITERATURE AND AIMS OF THE 
CURRENT STUDY 
 
1.1 Introduction and literature review 
“The penis does not obey the order of its master, who tries to erect it or shrink it at will. 
Instead, the penis erects freely while its master is asleep. The penis must be said to 
have its own mind, by any stretch of the imagination.” 
                                                                                          Leonardo da Vinci 
 
1.1.1 Introduction 
Erectile dysfunction (ED) is defined as the persistent inability to attain and 
maintain an erection adequate for satisfactory sexual performance (Feldman et 
al 1994).ED affects up to 52% of men between 40 and 70 years, and is an 
important cause of a decreased quality of life in men (Laumann et al 1999, Litwin 
et al 1998). Of the 52% of men with ED in a community prevalence study of 1709 
men (Massachusetts Male Aging Study), 17,2% had minimal ED, 25,2% 
moderate and 9,6% complete ED (Feldman et al 1994). 
 
It is estimated that by the year 2025, 322 million males will be affected by erectile 
dysfunction, the largest increase will be in the developing world: Africa , Asia and 
South America (Ayta et al 1995). The overall prevalence of ED in the MALES 
study involving 2912 men between the ages of 20-75 years was 16% (Rosen et 
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al 2004). The prevalence of self-reported ED increased with age. Men with co-
morbid disease and risk factors including cardiovascular disease, hypertension, 
dyslipidaemia and depression all reported higher prevalence of ED. Men with ED 
also reported increased prevalence rates of these co-morbid conditions. The 
prevalence of diagnosed hypertension, hyperlipidaemia, diabetes mellitus and 
depression in men with ED has been further quantified (Seftel et al 2004). In 272 
325 men with ED the prevalence rates for hypertension were 42,4%, for 
hyperlipidaemia 20,2%, for diabetes mellitus 11,1% and for depression 23,9%. 
Only 32% had none of the above co-morbid illnesses. 
 
One of the most significant advances in research into ED is the awareness of the 
high prevalence of ED in men with cardiovascular disease. In the Framingham 
Heart Study, a long-term cardiovascular study, the life-time risk of coronary 
artery disease in men at age 40 was 50% (Lloyd-Jones et al 1999). It is therefore 
possible that in this group half of the men could develop coronary heart disease 
and half could develop ED. The incidence of ED appears to be significantly 
higher in patients suffering from coronary artery disease (CAD), therefore some 
authors have proposed screening CAD patients for ED or vice versa (Levine et al 
2000). Patients with established CAD experienced ED symptoms on average two 
to three years before the onset of coronary symptoms, suggesting that ED may 
be a warning sign or an opportunity for early intervention (Montorsi et al 2006). 
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1.1.2 Pathophysiology of erectile dysfunction 
Endothelial pathology often leads to erectile dysfunction and the degree of ED 
varies directly with the number of atherosclerotic risk factors including 
hypertension, dyslipidaemia, diabetes mellitus and smoking (Virag et al 1985). 
These authors found that lesions in the pudendal arteries were more common in 
men with ED compared with controls of similar age. Atherosclerotic arterial 
occlusive disease of the hypogastric-cavernous-helicine tree can decrease the 
perfusion pressure and arterial flow to the sinusoidal spaces thus increasing the 
time to maximal erection and decreasing the rigidity of the erect penis (Lue 
2007). 
 
Hypertension is an independent risk factor for ED, and its consequent 
cardiovascular complications such as coronary heart disease and renal failure 
further worsen ED (Feldman et al 1994). It is the stenotic lesions found in the 
arterial tree that cause ED in hypertensive patients rather than the blood 
pressure itself (Hsieh et al 1989). A narrowed lumen or increased wall-to-lumen 
ratio in the arteries contributes to the increased peripheral vascular resistance in 
hypertensive subjects. This increased resistance has been documented in the 
penile vasculature of hypertensive rats, an alteration ascribed to structural 
changes in the arterial and erectile tissues (Hale et al 2001). In arteriogenic ED, 
oxygen tension in cavernosal blood is decreased thereby impairing the 
production of prostaglandin E1  and E2 and enhancing TGF-β1 (transforming 
growth factor) induced collagen synthesis (Nehra et al 1999). It is well known 
that enhanced sympathetic activity forms part of the pathophysiology of 
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hypertension leading to increased basal tone in the vascular smooth muscle and 
even smooth muscle hypertrophy.  
 
Diabetes mellitus is a common, chronic medical disease affecting up to 2% of 
people worldwide.  The prevalence of ED is three times higher in diabetic men, 
occurs at an earlier age and increases with disease duration (Feldman et al 
1994). Diabetes causes ED by affecting one or more of the following: nervous 
system function, androgen secretion, endothelial dysfunction and smooth muscle 
contractility (Dunsmuir et al 1996). Important components of diabetes induced 
ED include a reduced nitric oxide synthetase, decreased efficacy of released 
nitric oxide and the presence of oxidative free radicals such as advanced 
glycosylation end-products (Saenz de Tejada et al 2004). 
 
1.1.3 The metabolic syndrome 
The metabolic syndrome (MS, syndrome X) is characterised by lipid storage 
abnormalities, insulin resistance, hypertension, glucose intolerance, central 
obesity is characteristic and overt diabetes (type 2) or atherosclerosis develop 
over time (Ford et al 2002). MS is therefore a major cause of cardiovascular 
disease that increases the risk of myocardial infarcts and cerebrovascular 
events. The concept of MS has existed for at least 80 years.  The syndrome of 
metabolic disturbances, all risk factors for cardiovascular disease, was first 
described by a Swedish physician Kylin in 1922 as a clustering of hypertension, 
hyperglycaemia and gout (Kylin 1922). Over the past 20 years the syndrome has 
 4
become one of the major public health challenges worldwide as the global 
epidemic of diabetes and obesity has occurred. 
 
MS brings with it an elevated risk of diabetes mellitus and cardiovascular 
disease, and may in fact predict future diabetes, and therefore strategies to 
prevent this global  epidemic are needed urgently (Zimmet et al2001). MS is a 
master of disguise as it presents in multiple ways according to the various 
components that make up the syndrome. These components exist together in an 
individual more often than would be expected by chance (Eckel et al 2005). 
 
Several research groups have attempted to define criteria for diagnosing MS. 
The first attempt came in 1999 when a WHO diabetes group proposed a 
definition that could be modified as more information becomes available (Alberti 
et al 1998).  The criteria had insulin resistance, impaired glucose tolerance or 
diabetes as essential components, together with at least two of: hypertension, 
raised triglycerides and/or low HDL cholesterol, obesity and microalbuminuria. A 
revised definition came from the US National Cholesterol Education Programme: 
Adult Treatment Panel III in 2001 (Adult Treatment Panel III 2001). It was 
designed to facilitate the diagnosis of high cardiovascular risk individuals, 
requiring the presence of three of the following criteria: central obesity, 
hypertension, raised triglycerides, low HDL-cholesterol and fasting 
hyperglycaemia. The different definitions inevitably led to confusion and lack of 
consistency between studies.  
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One problem has been the difficulty in explaining the underlying mechanisms of 
MS (IDF Epidemiology Task Force Consensus Group 2005). It is not known 
whether to define MS according to insulin resistance, the metabolic 
consequences of obesity, risk for cardiovascular disease or a collection of 
related factors. A further problem with the above definitions was their lack of 
applicability to different ethnic groups particularly as relates to obesity or waist 
circumference cutoffs. One example is in the Asian population where the risk of 
diabetes is apparent at lower levels of obesity than in the European population 
(Tan et al 2004). The above two definitions would underestimate the prevalence 
of MS in the Asian population. 
 
The International Diabetes Federation (IDF) realised the need for one practical 
definition that could be applied to any country to assess the risk of diabetes and 
cardiovascular disease (2005). This definition would allow comparative studies 
between two different population groups. The IDF Consensus Group met in 2004 
and their new worldwide definition of MS is used in the current study. They 
agreed that diabetes and insulin resistance had been overemphasised in 
previous definitions and measurement of insulin resistance was deemed 
impractical. It was stated that certain components such as waist circumference 
and triglycerides are highly correlated with insulin sensitivity. Central obesity as 
assessed by waist circumference is regarded as essential due to its strong link to 
cardiovascular disease. 
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 Ethnic-specific waist circumference was incorporated into the definition and the 
values for males are given below: 
 
Ethnic group                                               Waist circumference (cm) 
Europeans                                                   ≥94cm 
South Asians                                               ≥90cm 
Chinese                                                       ≥90cm 
Japanese                                                     ≥85cm  
South and central Americans                      As for Asians 
Sub-Saharan Africans                                 As for Europeans 
Mediterranean, Middle East                        As for Europeans 
 
Ethnicity is based on classification, not country of residence. If body mass index 
is above 30 kg/m², central obesity can be assumed, and waist circumference 
does not need to be measured. 
 
The other variables in the definition are included below, the presence of any two 
along with central obesity are required for a diagnosis of MS to be made: 
 
Raised triglycerides 
>1,7 mmo/l 
Specific treatment for this abnormality 
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Reduced HDL-cholesterol 
<1,03 mmol/l in men 
Specific treatment for this abnormality 
 
Raised blood pressure 
Systolic ≥130 mmHg 
Diastolic ≥85 mmHg 
Treatment of previously diagnosed hypertension 
 
Raised fasting plasma glucose 
Fasting plasma glucose ≥5,6 mmol/l 
Previously diagnosed type two diabetes 
Oral glucose tolerance test is not necessary to diagnose MS 
 
(IDF Consensus Group 2005) 
 
Recently the American Diabetes Association and the European Association for 
the Study of Diabetes have published an article on the syndrome (Kahn et al 
2005). They raise three questions regarding MS: 
1. Is it indeed a syndrome, particularly as the cause of MS is yet to be 
defined? 
2. Does it serve a useful purpose? 
3. Is it labelling a person unnecessarily? 
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The IDF, however feel strongly that the clustering of closely related risk factors 
for cardiovascular disease and diabetes is a good basis for calling this a 
syndrome. Many conditions have been given a name without the underlying 
cause being known, for example type two diabetes. The epidemic of 
cardiovascular disease and diabetes worldwide seems enough reason to identify 
people with the syndrome as an opportunity exists to manage the components of 
MS if recognised early (IDF Epidemiology Task Force Consensus Group 2005). 
 
The prevalence of MS is highly age dependent. In a US study the prevalence of 
MS increased from 7% in participants aged 20-29 years to 44% for those aged 
60-69years (Ford et al 2002). Several studies have shown that MS predicts 
future development of diabetes and cardiovascular disease as well as mortality 
from these conditions. In the DECODE study in Europe involving non-diabetic 
participants, those with MS had an increased risk of all-cause and cardiovascular 
mortality compared to those without it . All-cause mortality was 1,44 times higher 
(95% confidence interval 1,17-1,84), while cardiovascular disease was 2,26 
higher (95% confidence interval 1,61-3,17) in men with MS (Hu et al 2004). 
 
 1.1.4 Erectile dysfunction and the metabolic syndrome 
It is postulated that an association between ED and MS exists as four of the five 
components of MS are risk factors for ED (Calermayer et al 1994).  In a 
European study ED prevalence increased linearly as the number of components 
of MS increased (Esposito et al 2005). The ED scores were significantly worse in 
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men with MS compared to those without in another recent study (Demir et al 
2006). 
 
The underlying causes of MS (and ED) include physical inactivity, obesity and 
genetic predisposition and several risk factors are common to both disorders 
(Roth et al 2003). Obesity is associated with insulin resistance and MS, 
abdominal obesity in particular is more highly correlated with insulin resistance 
and may reflect a strong genetic component to MS. The most accepted and 
unifying hypothesis to incorporate the pathophysiology of MS is insulin 
resistance (Eckel et al 2005). Insulin resistance has been defined as a defect in 
insulin action resulting in fasting or postprandial hyperinsulinaemia to maintain 
normal glucose concentrations. A major contributor to the development of insulin 
resistance is an excess of circulating fatty acids (Eckel et al 2005). Obesity is 
associated with hypogonadism in males due to an increased aromatase activity 
causing low libido, depression and less frequent intercourse (Roth et al 2003).  
 
Insulin resistance reduces the concentration of lipoprotein lipase in peripheral 
tissue, particularly adipose tissue. This along with an overproduction of very low-
density lipoproteins contributes to hypertriglyceridaemia (Eckel et al 2005).  In 
the Massachusetts Male Aging Study baseline obesity predicted a higher risk for 
ED regardless of follow-up weight loss. Physical activity was also associated with 
ED, with the highest risk among men who remained sedentary and the lowest 
among those who initiated activity or stayed active (Feldman et al 1994). In a 
study by Derby et al 2000, the prevalence of complete ED amongst cigarette 
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smokers was not significantly different to that amongst non-smokers, however 
cigarette smoking increased impotence associated with cardiovascular disease, 
hypertension and medication use.  
 
The other major lipoprotein disturbances in MS include an increased clearance 
of high-density lipoproteins and a predominance of small dense low-density 
lipoprotein (Eckel et al 2005). In MS and dyslipidaemia, low density lipoprotein 
(LDL) production destroys endogenous nitric oxide synthetase, leading to a 
decreased bioavailability of nitric oxide on the endothelial surface which results 
in vasoconstriction (or inhibition of vasodilation) and damaged endothelium (early 
atherosclerosis) (Kim 2000, Wheatcroft et al  2003). Nitric oxide inhibits 
atherogenesis, thrombogenesis, platelet adhesion, lipid peroxidation and 
monocyte adhesion. A good arterial inflow of blood along with efficient venous 
trapping of blood is required for normal erections to occur. This vascular function 
relies heavily on nitric oxide bioavailability. Endothelial dysfunction, defined as a 
reduced biovailability of nitric oxide is associated with many of the common risk 
factors for ED and cardiovascular disease (Ker 2006), see figure 1.1.  
Endothelial dysfunction leads to early atherogenesis and insulin resistance 
(Chaula 2004). Superimposed and contributory to the insulin resistance 
produced by the lipoprotein abnormalities, is the effect of a pro-inflammatory 
state. The increased secretion of interleukins and tumour necrosis factor from 
adipose tissue results in more insulin resistance and lipolysis of triglycerides 
(Eckel et al 2005). The cytokines and lipoproteins increase the production of pro-
thrombotic markers from the liver, for example fibrinogen and plasminogen 
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activator inhibitor-1. ED and vascular disease are clearly linked at the level of the 
endothelium and the presence of ED in asymptomatic men may be a marker of 
silent cardiovascular disease. 
 
 
 
Figure 1.1 Endothelial dysfunction 
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1.1.5 Erectile dysfunction score 
Assessing the severity of ED has been made more accurate by the development 
of standardised questionnaires, most of which are self-administered. The 
International Index of Erectile Function (IIEF) is a brief, reliable, self administered 
measure of erectile function. It is a cross-cultural, psychometrically sound, 
reliable assessment with proven validity (Rosen et al 1997). It has been validated 
in many languages and is the most widely used self-administered questionnaire 
for sexual function. It measures five domains of sexual function in males namely 
erectile function, orgasmic function, sexual desire, intercourse satisfaction and 
overall satisfaction in fifteen questions (Appendix 7). 
 
An abridged five item version of the original fifteen item version has been 
specifically validated for use in ED (Rosen et al 1999) and is used in the current 
study. ED is classified into five categories based on IIEF-5 scores: severe (5-7), 
moderate (8-11), mild to moderate (12-16), mild (7-21) and no ED (22-25). The 
most important difference between IIEF-15 and IIEF-5 is that the latter assesses 
ED over the last six months as opposed to the last four weeks, a more clinically 
relevant and practical time frame (Appendix 3). 
 
The metabolic syndrome has recently become one of the major public health 
challenges and results from the increasing prevalence of obesity. Men with co-
morbid disease and risk factors including cardiovascular disease, hypertension, 
dyslipidaemia all report a higher prevalence of ED. 
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1.2 Problem  statement 
There is no research from tertiary care hospitals in South Africa evaluating the 
prevalence of MS in men presenting with ED. International studies may not be 
applicable in our setting. The total impact that MS has on men’s health in South 
Africa is still unknown and needs to be more clearly defined. ED is probably the 
most sensitive barometer of men’s health worldwide, and several new insights 
will allow us to see ED as part of a broader health risk and not as an isolated 
dysfunction. 
 
1.3 Significance of the study 
This study will provide an overview of the prevalence of MS in males presenting 
with ED to a South African tertiary hospital. The impact that these disorders have 
on the health budget is significant, particularly in the developing world, and early 
detection via screening will help introduce preventative strategies to curtail the 
consequences that impact so heavily on quality of life. 
 
1.4 Research questions 
 What is the prevalence of MS in males presenting with ED to a South African 
tertiary hospital? 
 Do males with MS and ED present with more severe ED, and which other 
factors contribute to ED duration and severity? 
 
1.5 Aims of the current study 
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 The primary aim of this study is to determine the prevalence of MS in males 
presenting with ED to a South African tertiary hospital. 
 A secondary aim of this study is to determine whether MS affects the severity 
of ED, and which other parameters affect the severity and duration of ED. 
 
1.6 Objectives of the current study 
1. To establish the proportion of males presenting with ED to the Men’s 
Sexual Dysfunction Clinic (MSDC) who also fit the criteria for the 
diagnosis of MS. 
2. To establish the proportion of males presenting with ED to the MSDC who 
do not fit the criteria for MS. 
3. Evaluate and compare the severity of ED in males with and without MS at 
the MSDC, by standardised questionnaire format. 
4. To determine which racial groups in South Africa are more at risk for ED 
and MS, and any ethnic-specific risk factors for ED duration and severity. 
5. To analyse the factors contributing to the duration and severity of ED in 
the South African male population 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
The following chapter includes a description of the research design used in the 
current study. The choice of subjects, including inclusion and exclusion criteria is 
discussed, a well as sample size and ethical considerations such as informed 
consent. All procedures followed during the history taking, physical examination, 
blood sampling and administration of the questionnaire are included. A brief 
summary of the statistical tests performed on the data is given at the end of the 
chapter. 
 
2.1 Research design 
Permission to conduct research on human participants was obtained from the 
Human Research Ethics Committee (Medical). Clearance certificate protocol 
number: M070737 (Appendix 5). Permission was also obtained from the 
Superintendent of the Johannesburg Hospital (Appendix 6). 
 
A clinic survey amongst males suffering from ED who presented to a tertiary 
hospital MSDC (Male Sexual Dysfunction Clinic) was conducted. The study was 
conducted at the Johannesburg Hospital MSDC, situated in the Out-patient 
Department, Area 456. Men may only attend this clinic once they have been 
referred from the Urology Out-patient Clinics at Johannesburg or Helen Joseph 
Hospitals. Men were invited to participate and were able to decline without being 
disadvantaged in anyway. They were provided with information about the study 
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and their questions were addressed. An interpreter was always available on site 
should the participant not be fluent in English. After reading the information 
leaflet (Appendix 1) and signing informed consent (Appendix 2), anonymity was 
maintained by allocating study numbers to the questionnaires and data collection 
sheets (see below). Names and hospital numbers did not appear on the 
questionnaires and data collection sheets. Participants did not receive any 
financial remuneration for participating in the study.  
 
 2.2 Subjects 
The first one hundred men presenting to the Johannesburg Hospital MSDC who 
met the study criteria and who agreed to participate were recruited. All racial 
groups were included and the final proportions of racial groups enrolled more or 
less resembles the population statistics of South Africa. The following criteria 
were used to determine whether the potential participant was eligible for the 
study. 
Inclusion criteria 
 Males above 30 years of age presenting with spontaneous-onset ED, defined 
as an inability to achieve and sustain erections adequate for sexual 
intercourse. 
Exclusion criteria 
 Prior pelvic surgery leading to onset of ED 
 Prior pelvic irradiation therapy leading to onset of ED 
 Prior major pelvic trauma leading to onset of ED 
 Spinal cord injuries 
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Th  above criteria weree  used to exclude men with ED due to non-spontaneous 
.3 Procedure 
a list of procedures followed during the first clinic visit at the 
causes, as even if these men had MS it would not be known whether the MS or 
another cause was responsible for their ED. 
 
2
The following is 
Johannesburg Hospital MSDC. 
 Men who met the inclusion criteria were invited to participate. 
 were 
rmation 
The study was explained to them and any questions they had 
addressed. They were given the opportunity to read through the info
sheet (Appendix 1). If necessary they were allowed to take this document 
home while considering their potential participation. If they agreed to 
participate, informed consent was signed (Appendix 2). 
 e principal 
e MSDC 
A thorough history and examination was performed by th
investigator. This was the routine history and examination done at th
for all patients during their first visit. 
 ge, race, sex and occupation was 
nd 
 
General demographic data such as a
collected. A smoking history, medical and surgical history, drug history a
ED duration was obtained. The above data was entered onto an anonymous
data collection sheet (Appendix 4). 
 performed on all participants. Parameters 
that were measured and recorded specifically for the study by the principal 
investigator were as follows : 
A general medical examination was 
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Waist circumference, measured with a horizontal tape measure halfway 
between the lowest rib and the iliac crest in the standing position, greater 
than 85-94 cm (depending on race) being a criterion for MS. 
h a 
/85 
Systolic and diastolic blood pressure measured in the seated position wit
manual sphygmomanometer cuff over the brachial artery, greater than 130
mmHg being a criterion for MS. 
Weight and height as measured with a calibrated electronic scale and tape 
measure respectively, with subsequent calculation of body-mass index (BMI 
kg/m²): 
BMI ranges: low < 18,5 ; normal 18,5-24,9 ; high 25-29,9 ; obese >30 
 
elow). 
The IIEF-5 was explained and completed by the participants (see tools 
section b
 re 
 by 
alth Laboratory Service, which is the routine biochemistry 
 a criterion for MS 
 than 1,03 mmol/l being a criterion for MS 
S 
     Fasting serum insulin levels as a measure of insulin resistance 
Blood specimens were collected by the clinic staff. These specimens a
routinely collected for all clinic attendees. The specimens were analysed
The National He
laboratory at the Johannesburg Hospital. The following serum tests were 
analysed, significant reference values are included : 
Fasting lipogram :  
Total cholesterol 
Triglycerides, greater than 1,7 mmol/l being
HDL, less
LDL 
Fasting glucose, greater than 5,6 mmol/l being a criterion for M
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     Glycated h
     Hormone profile:  
                                                    
ormone 
timulating Hormone 
Should res e 
called bac
Participant heir next clinic visit regarding any abnormal 
results or a d. Contact details are kept among 
aemoglobin 
Testosterone (morning specimen): less than 12 nmol/l indicates 
hypogonadism                                                              
Luteinising H
Follicle S
ults be available for non-fasting specimens only, participants wer
k for fasting specimens to be drawn.    
s were counselled at t
lternatively they were contacte
clinic records. 
 te c llectio  form Appendix All of the above data was recorded on a separa o n  (
4). 
  
nics at the Johannesburg Hospital for example Diabetes, 
us, for example an electrocardiogram would be performed at the relevant 
Participants with significant, newly diagnosed abnormalities were referred to
the relevant cli
Hypertension and Lipid Clinic. Further assessment of their cardiovascular 
stat
clinics and was not done for the present study. 
 
 
 
A diagnosis of type 2 diabetes, hypertension or lipid abnormality is 
accommodated within the definition of the metabolic syndrome. The IDF 
criteria (2005) for the diagnosis of MS, as included in the literature review, 
were used to diagnose MS. 
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2.4 Tools  
 International Index of Erectile Function (IIEF) is a brief, reliable, self-
inistered measure of erectile function that is cross-cultural, psychometrical
The
adm ly 
sound and has been validated (Rosen et al 1997, Appendix 7). An abridged five 
em version has been developed (IIEF-5) to assess ED more specifically as 
pposed to overall sexual function (Rosen et al 1999, Appendix 3). ED is 
to ive categories based on IIEF-5 scores: severe (5-7), moderate (8-
 1985). 
 / 22,5. Higher 
 have a score 
n 
uous variable) and plotted graphically.   
  
it
o
classified in  f
11), mild to moderate (12-16), mild (7-21) and no ED (22-25). 
 A data sheet was used to record participant demographics, relevant history and 
examination, measurements taken and blood results (Appendix 4). 
In each participant, the degree of insulin resistance was estimated by HOMA 
(homeostasis model assessment) insulin resistance score (Matthews et al
The HOMA-IR score was computed with the following formula:  
fasting plasma glucose (mmol/l) x fasting plasma insulin (mU/l)
values indicate insulin resistance and the present cut-off for the diagnosis of 
insulin resistance is 2,5. Normal subjects with normal weight should
of 1. 
 
2.5 Analysis of data 
Data was recorded in EXCEL and analysed using SAS Version 9.1. Data is 
reported as mean±std or as number (frequency). Where applicable, correlatio
between variables was determined (e.g. degree of IIEF (rank variable) and 
contin
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2.6 Time frame  
The MSDC runs on a weekly basis with an average of ten men seen weekly.
Every  week on average three to five first time attendees are seen, who were 
invited to participate. Data collection was completed within a period six mon
The data collection began as soon as permissi
 
ths. 
on had been granted by the 
vant committees. 
erformed over and above the routine tests performed at 
SDC, therefore no additional costs were incurred. Printing and stationery costs 
 investigator. No grants or sponsorships were 
rele
 
2.7 Costing and resources 
All participants were regular clinic attendees and incurred no extra cost in 
participating in the study. Clinic equipment was used to perform the 
measurements (tape measure, scale, sphygmomanometer). No additional 
laboratory tests were p
M
were covered by the principal
obtained, and there was no conflict of interest. 
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CHAPTER THREE 
ESULTS 
he following chapter presents the results for the current study. Participants are 
ivided into three large population groups, namely Black, White and a third group  
ontaining participants of Asian, Chinese and Coloured people of South African 
rs in the three groups are approximate reflections of official 
tatistics in South Africa, although this was unintentional. The first 100 
ompleted assessments are included in the data, and this includes 61 black, 15 
r than 
00 participants, 32 
ere retired, 14 were unemployed and the remaining 54 were employed. 
 
R
 
T
d
c
descent. The numbe
population s
c
white and 24 participants in the third group which is referred to as the Other 
group henceforth for ease of reference. A total of 107 participants were assessed 
but 7 were excluded due to incomplete data sets. The reasons for these 
exclusions included laboratory errors and lost specimens. 
 
3.1 Demographic data 
The demographics of the study sample are shown in Table 3.1.  
 
The average age of participants in the White group was significantly highe
in the other groups (p=0,02) as shown by ANOVA. Of the 1
w
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Table 3.1 Demographic data 
 
BLACK 
 n=61 
WHITE  OTHER 
n=15  n=24 
AVERAGE AGE IN YEARS (SD) 
56,7 (13,6) 69,6 (9,1) 59,8 (11,2) 
AGE RANGE IN YEARS 
30-83 56-81 44-77 
SD     Standard deviation 
 
3.2 Past medical histo
The nu icipants present o-morbid medica
associated with ED risk is p ication use amongst 
participan ded diuretics, alpha and beta blockers, calcium-channel 
lockers, ACE inhibitors, nitrates, statins and oral hypoglycaemic agents.  
 the Black group, 27(44%) participants were smokers with a mean15 pack-year 
 participants had a mean smoking history of 27 pack 
 pack-
e 
ing 
 
ry 
mber of part ing with a c l illness 
resented in Table 3.2. Med
ts inclu
b
 
In
history, while 7(47%) White
years and 12(50%) participants in the Other group had an average of 22
years. In addition, 3 Black men had a past or current history of marijuana us
and 1 smoked a tobacco pipe. One Asian man had a significant pipe-smok
history. 
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Table 3.2 Past medical history 
 
 BLACK 
 n=61(%) 
WHITE 
 n=15(%) 
OTHER 
 n=24(%) 
Co-morbid illnesses 28(46) 12(80) 18(75) 
Hypertension 26(43) 9(60) 14(58) 
Diabetes (type 2) 9(15) 2(13) 8(33) 
Hypercholesterolaemia 1 5(33) 2(1) 
Epilepsy 1 0 0 
BPH 15(25) 3(20) 0 
IHD 0 3(20) 5(21) 
CRF 0 1 1 
 
BP  hyperpla         IHD     mic heart di
e 
 
3.3  Physical characteristics 
The measurements performed during the physical e ation are su
in Table 3 ong the Black part
0kg/m², as did 2(13) White participants and 6(25) participants in the Other 
 (p=0,91). Those participants with central obesity as 
efined by IDF criteria according to their race, included 30(50) Black, 11(73) 
ants. 
H    Benign prostatic sia      Ischae sease 
CRF    Chronic renal failur
xamin mmarised 
.3. Am icipants, 12(20) had a body mass index above 
3
group making them by definition obese. The overall BMI values did not differ 
significantly between groups
d
White and 15(63) Other particip
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Table 3.3 Physical characteristics 
 
BLACK 
 n=61 
WHITE 
 n=15 
OTHER 
 n=24 
AVERAGE WEIGHT (Kg) (SD) 
78,2 (22,0) 81,9 (12,6) 78,1 (19,6) 
AVERAGE HEIGHT (cm) (SD) 
169,4 (7,8) 176,1 (5,2) 171,3 (9,3) 
AVERAGE BMI (Kg/m²) (SD) 
27,1 (6,4) 26,4 (4,0) 27,0 (6,2) 
AVERAGE WAIST CIRCUMFERENCE (cm) (SD) 
93,0 (15,0) 100,2 (12,2) 98,6 (16,7) 
WAIST CIRC E RANGE (cm) UMFERENC
64-150 80-131 76-129 
AVERAGE HIP CIRCUMFERENCE (cm) (SD)  
101,1 (11,8) 105,0 (7,5) 102,3 (13,6) 
AVERAGE P RATIO (SD)  WAIST/HI
0,91 (0,07) 0,95 (0,06) 0,96 (0,07) 
AVERAGE BLOOD PRESSURE (mmHg)  
133/84 130/86 134/83 
 
SD      Standard 
Kg       Kilogram                          MI body mass in
cm       centimetre                                        mmHg  millimetres mercury 
deviation                             m   metre 
                  B dex 
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Overall waist-to-hip ra n groups as shown 
by A 08). Blood pre recorded for those  who 
were not taking an  hypertension. 
Those tihypertensives or evious diagnosis of hy ion 
utomatically qualify as a component of MS diagnosis. Neither the systolic nor 
by ANOVA (p=0,95 and 
ple 
te relationships between ED duration and other measured 
arameters were performed. ED duration correlated with a number of 
 on ethnic origin. 
re 
,03). In 
duration. 
tios were significantly different betwee
NOVA (p=0,0 ssures were  participants
antihypertensive or had no prior diagnosis of
taking an with a pr pertens
a
diastolic values differed between the groups as shown 
0,91 respectively). 
 
3.4  Erectile function 
 Figure 3.1 shows the average IIEF score as well as the average duration of ED 
amongst the three groups. The average ED duration in years does not differ 
statistically between groups as shown by ANOVA (p=0,12), with the total sam
having an average ED duration of 3,8 years (4,0) and individual group means 
(SD) of 3,2(3,7), 4,7(3,8) and 5(4,7) respectively. Pearson correlation co-
efficients of univaria
p
parameters dependent
 
In the Black group, ED duration correlated inversely with systolic blood pressu
(r=-0,383; p=0,02), triglyceride level (r=0,240; p=0,06) and HDL (r=-0,279; 
p=0,03). In the White group ED duration correlated significantly with glucose 
(r=0,557; p=0,03), HbA1c (r=0,583; p=0,02) and cholesterol (r=0,572; p=0
the Other group no statistically significant correlations were found with ED 
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010
12
Black White Other
2
4
6
8
IIEF score ED dur (yr)
 
 
Figure 3.1 Erectile function 
 
When all participants were included ED duration correlated significantly with 
triglycerides only (r=0,188; p=0,06) and not with blood pressure. However, once 
adjusted for HDL, triglycerides, glucose, HbA1c, HOMA and waist to hip ratio, 
ED duration correlated inversely with systolic blood pressure (r=-0,337; p=<0,02) 
but the inverse relationship with diastolic blood pressure was not statistically 
significant (r=-0,21; p=0,16). For all participants multivariate analysis showed 
fter adjusting for co-variates, glucose (p=0,013) and HbA1c (p=,0001) to be 
uration. Figure 3.2 shows the proportion of 
articipants in each group presenting with mild (17-21), mild to moderate (12-16), 
moderate (8-11) and severe (5-7) ED according to their IIEF scores. 
a
significant predictors of ED d
p
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05
15
20
10
25
mild mild-mod mod severe
Black
White
Other
e, smoking history, ED duration, HDL 
nd waist to hip ratio showed a strong correlation with IIEF score. When 
ng to 
 
Figure 3.2 Severity of ED in each group  
 
Average IIEF scores (SD) per group were 9,1(3,4); 10,0 (6,1) and 9,4 (3,6) 
respectively. These scores were not statistically different between the groups as 
shown by ANOVA (p=0,74). All three groups had a predominance of participants 
with moderate or severe ED. All the groups had participants with the most severe 
ED (IIEF score of 5), while the highest scores in each of the three groups were 
18, 22 and 17 respectively. Pearson correlation co-efficients of univariate 
relationships between IIEF score and other measured parameters were 
performed within ethnic groups. Although no correlations reached statistical 
significance (p<0,05) LH, testosterone, ag
a
participants were divided into three groups (mild, moderate, severe) accordi
IIEF scores, there was no correlation between ED duration and ED severity 
(p=0,43). Age was a strong but not significant predictor of ED severity within 
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these groups (p=0,07). No other parameters within the lipogram or hormone 
profile were significant predictors of ED severity. 
 
3.5  Fasting lipogram 
The results from the fasting lipogram are depicted in Table 3.4. All values are
given in mmol/l (standard deviations).   
 
  Table 3.4 Fasting lipogram        
 
 
 ALL 
n=100 
BLACK  
n=61 
WHITE  
n=15 
OTHER  
n=24 
Cholesterol 4,5(1,2) 4,4(1,2) 4,3(07) 4,9(1,3) 
Triglycerides 1,5(1,0) 1,4(1,0) 1,3(0,6) 1,8(1,1) 
HDL 1,2(0,3) 1,2(0,3) 1,3(0,3) 1,2(0,3) 
LDL 2,6(1,1) 2,5(2,0) 2,5(0,6) 3,1(1,3) 
 
 
 Other group did not reach statistical 
ignificance as shown by ANOVA (p=0,18). The higher triglyceride value in the 
O er group was not sig ntly high n by p=0,15
was clearly no significa ence in g DL (p=0  shown b VA. 
The higher LDL value in the Other gro d towa ever re
statistical significance as sho OVA.
 
 
The higher cholesterol value in the
s
th nifica er as show ANOVA ( ). There 
nt differ roup H ,57) as y ANO
up tende rds but n ached 
 (p=0,07) wn by AN  
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3.6  Indices of glucose metabolism  
Figure esents th from th  blood taken f e 
mol/l), insulin (IU/l), HbA1c (%) and the calculated HOMA scores from these 
amples. Mean values per group are depicted graphically. 
3.3 pr e results e fasting samples or glucos
(m
s
 
2
4
8
18
6
10
12
14
16
Black
White
Other
 
0
Glucose Insulin HOMA HbA1c
 
Figure 3.3 Indices of fasting glucose metabolism per group 
 
The mean (SD) values for the total population were as follows: glucose 5,9 
mmol/l (3,1); insulin 10,9 IU/l (13,4); HOMA 3,0 (4,0) and HbA1c 6,5 % (2,1). 
Insulin levels were significantly higher amongst participants in the Other group as 
shown by ANOVA (16,7 compared to 9,5 and 9,0; p=0,049). HOMA scores were 
significantly higher in the Other group as compared to the first two groups as 
shown by ANOVA (mean of 5,5 compared to2,2 in the first two groups, p=0,002). 
Glucose concentration differences between groups were of borderline 
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significance (p=0,05). HbA1c levels did not differ between groups as shown by 
3.5. 
ANOVA (p=0,17). 
 
3.7  Endocrine parameters 
The endocrine parameters testosterone, FSH and LH are presented in Table 
The four values in each group represent the mean (standard deviation), 
minimum and maximum. 
 
Table 3.5 Endocrine parameters 
 
 TOTAL BLACK   WHITE   OTHER  
n=100 n=61 n=15 n=24 
TESTOSTERONE 
(μmol/l) 
15,4 (6,6)  14,9 (6,2) 17,2 (7,7) 15,6 (6,9) 
 4,0 / 35,9 4,0 / 28,4 5,2 / 29,1 7,3 / 35,9 
FSH 
(IU/l) 
6,5 (7,7) 
0,8 / 69,7 
4,9 (3,1) 11,0 (17,5) 7,9 (5,1) 
0,8 / 18,6 2,0 / 69,7 2,9 / 20,9 
LH 5,5 (5,1) 4,5 (2,2) 8,3 (11,7) 6,5 (2,9) 
(IU/l) 1,6 / 44,2 1,6 / 15,2 2,0 / 44,2 2,3 / 12,2 
 
FSH      Follicle Stimulating Hormone (1,4-18,1 IU/l) 
LH         Luteinising Hormone (<70y: 1,5-9,3 IU/l; >70y: 3,1-34,6 IU/l) 
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Testosterone levels di igni een 0,4
Hypo  (define m te  less ol/l)
present in 23 Black (38%), 6 White (40%) and 8 Other (33%) participants. The 
mean (SD) LH concent l groups
means being significantly different between groups as shown by ANOVA 
(p=0,02
 
.8  The metabolic syndrome 
l Diabetes Federation 
dy 
opulation. The ethnic specific criteria were applied to all three groups. As 
or 
 
 the study population, 20 of 61 (33%) Black participants were diagnosed with 
ts had no prior medial history and were not on 
er 
. Of 
15 
 
medications. There were 2 type two diabetics amongst the remaining 4, all of 
d not differ s ficantly betw  groups (p= 6). 
gonadism d as a seru stosterone  than 12 μm  was 
ration for al  was 5,5 (5,1), with individual group 
1). 
3
As discussed in the methods section, the Internationa
(2005) criteria were used to determine the prevalence of MS in the stu
p
mentioned in an earlier section, those individuals already on medication f
hypertension and lipid abnormalities as well as a prior diagnosis of type two
diabetes mellitus were considered to have one or more positive criteria for the 
diagnosis of MS. Two or more of these criteria along with central obesity is 
required for the diagnosis of MS.  
 
In
MS. Five(8%) of these participan
any chronic medications. Seven(11) of these participants were known to suff
from type two diabetes, while 13(21) had a prior diagnosis of hypertension
these 20, 8 were hypogonadal (40%). Amongst the White participants, 6 of 
(40%) participants had MS. Two of these 6 had no medical history or chronic
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which also suffered from hypertension. Of the 6 with MS, 3 were hypognadal
(50%). Amongst the Other group 6(25) participants had no prior medical history
while 5(21) had a prior diagnosis of diabetes and 10(42) were already on 
treatment for hypertension. This gr
 
, 
oup had the highest prevalence of MS with 13 
f 24 (54%) participants. Of these 13, 6 were hypogonadal (46%). The 
 
D). 
o
prevalence of MS in the total study sample was therefore 39 of 100 participants 
(39%). Table 3.6 shows some differences in parameters between participants 
with and without MS. No significant correlation was found between ED duration,
severity and presence of MS when adjusted for cholesterol, HDL, triglycerides, 
glucose, HOMA and HbA1c. 
 
Table 3.6 Comparison between participants with and without MS (mean and S
 
 MS 
 n=39 
No MS 
n=61 
AGE 62,7(11,7) 57,1(13,7) 
TESTSTERONE (μmol/l) 14,1(5,8) 16,3(7,0) 
LH (IU/l) 4,8(2,0) 6,0(6,5) 
FSH (IU/l) 6,5(4,0) 6,6(9,6) 
IIEF score 9,2(4,1) 9,4(3,9) 
ED duraton 4,3(4,1) 3,5(3,9) 
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CHAPTER FOUR 
ISCUSSION 
 
This chapt usses the results o e previous chap  are 
r as they ented and not ne  the 
order of importance, however a more discussion on the  
aspects of the study is given in order e objectives and aims of the study. 
Empha  on the statisticall nt findings from th nd 
other parameters that did not reach s e but are particula ting or 
ontradictory are discussed. Included in the discussion are some limitations of 
e study and recommendations for future research. 
 conducted in a South African tertiary care centre has been 
udy enrolled one hundred participants, all men over the age of 
irty with varying degrees of erectile dysfunction. A thorough history, physical 
 the 
 reflections of the 
opulation statistics in South Africa, although this was unintentional. The varying 
D
er disc utlined in th ter. Results
discussed in the same orde  were pres cessarily in
 detailed important
 to fulfil th
sis is placed y significa e study a
ignificanc rly interes
c
th
 
A prevalence study
outlined. The st
th
examination, questionnaire administration and serum tests were performed in 
order to identify risk factors for ED, severity of ED and the prevalence of the 
metabolic syndrome. The data was collected over a period of six months at
Johannesburg Hospital Male Sexual Dysfunction Clinic. 
 
4.1 Demographic data  
The 100 participants were divided into three population groups according to 
ethnicity. The numbers in the groups are approximate
p
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numbers of participants per group, 61,15 and 24 makes analysis of results 
between groups more complex and sample sizes smaller if the data sets are 
considered separately. The emphasis is placed on the total sample, being 100 
South African men of different ethnicity. 
 
The average age of the sample is 59 years which is in keeping with the 
population presumed to be at risk for primary ED. The significantly higher age 
mong White participants may alter the results somewhat, if it is assumed that 
d to more degenerative diseases and may have more 
are 
the 
d, 
here is a very high prevalence of co-morbid diseases amongst the participants. 
 
of 
a
older men are predispose
cardiovascular and hence ED risk factors. Maximum ages across the groups 
similar, although the youngest Black participant (30 years) is well below 
youngest participant in the other two groups. Age did not significantly affect the 
severity of ED when separate age cohorts and IIEF-5 scores were compare
although it was a strong predictor (p=0,07). 
 
4.2 Past medical history 
T
As discussed in the literature review cardiovascular risk factors such as 
hypertension, diabetes mellitus and hypercholesterolaemia are also risk factors
for ED (Levine et al 2000; Rosen et al 2004; Seftel et al 2004). The prevalence 
these co-morbid diseases in the three groups is 46%, 80% and 75%. As a 
comparison in Rosen’s study of almost 300 000 men with ED, only 32% did not 
have one of the above co-morbid diseases. Perhaps surprisingly, the lower 
prevalence of co-morbid illnesses among Black participants is not associated 
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with a less severe ED (IIEF 9,1; p=0,74) compared to the other two groups. 
Smoking habits and number of pack years among participants are similar 
etween groups. The higher pack year history amongst White participants is 
ean age in this group.  According to the latest 
 
 the 
een 
9,9 
one. 
. The 
 developing ED. 
 obesity as defined by IDF criteria according to 
their race, included 30(50%) Black, 11(73) White and 15(63) Other participants. 
b
likely related to the higher m
Demographic and Health Survey in South Africa, the percentage of South African 
males currently smoking was 31,1% (Department of Health 2003). The 
prevalence of smoking in the current sample is therefore higher than the national
prevalence, which could be a contributing factor to the ED in almost half of the 
participants.  
 
4.3 Physical characteristics 
During the physical examination, weight and height measurements were 
performed in order to calculate the body mass index. The average weight for
total sample is 78,4 kg  with no differences in height, weight and BMI betw
groups. The average BMI for all the groups falls within the high range (25,0-2
kg/m²). Overall 20 participants were classified as obese just by their BMI al
One Black participant weighed 200kg with a calculated BMI of 61 kg/m², this 
outlying measurement may have skewed the results for the Black group
lightest participant weighed just 50 kg, with the lowest BMI for the sample being 
17,1 kg/m². These results appear to confirm that no body morphology is 
excluded from
 
Those participants with central
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As mentioned during the discussion of the IDF criteria for MS, a large ethn
specific waist circumference is a prerequisite for the diagnosis of MS. Of the 56 
participants with a large ethnic-specific waist circumference, 39 were found to 
have MS. Hip circumference is included in the assessment as a control measure 
for waist circumference. Waist circumference and waist-to-hip ratios are lowest in
the Black group (p=0,008) and it is not surprising therefore that this is the only
group in which ethnic-specific waist circumference falls below the IDF cut-off fo
central obesity (93 cm vs 94 cm). The other two groups have average waist 
circumferences well above central obesity levels (100,2 cm vs 94cm and
vs 90 cm respectively). The new
ic-
 
 
r 
 98,6 cm 
 IDF criteria introduced the lowest waist 
ircumference measurements for people of Asian descent (<90 cm), yet in the 
ce 
nt 
onent 
c
current sample, the Other group has a much higher average waist circumferen
than the Black group. It is not surprising therefore that the Other group has the 
highest prevalence of MS (54%). 
 
Blood pressure measurements are less useful in the current study as a 
significant proportion (49%) of the participants were taking an antihypertensive at 
the time of assessment. Blood pressures were recorded in the remaining 51 
participants but showed no differences between groups. The average systolic 
(133 mmHg) and diastolic (84 mmHg) values are not that raised considering the 
population being assessed. Blood pressure does form an important compone
of MS diagnosis with levels above 130/85 mmHg being diagnostic. The fact that 
49 participants were taking treatment for hypertension qualifies as a comp
for MS diagnosis regardless of measurements.  
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4.4 Erectile function 
The average duration of ED is highest among the Other group (5 years) althoug
not significantly longer than the tot
h 
al average of 3,8 years. ED duration correlates 
ith several parameters of the fasting lipogram and indices of glucose 
ose and 
e in South Africa or a 
t to seek help for a private matter such as ED. 
en 5-11). 
s 
nted 
h none 
S 
w
metabolism, although these are mostly ethnic specific correlations. Gluc
HbA1c appear to correlate strongly with ED duration and these parameters 
would be part of the initial diagnostic workup for men presenting with ED 
worldwide. The lack of correlation (and in fact an inverse correlation) between 
blood pressure and ED duration or severity should be interpreted with caution as 
blood pressure was measured as a once off reading in only half of the 
participants. What is surprising is the length of time from disease onset to first 
presentation at the clinic (average 3,8 years) which may reflect the lack of 
access that some individuals have to medical car
reluctance on their par
 
 Late presentation of illness may also be assumed when one considers that 80% 
of participants had moderate to severe ED based on IIEF scores (betwe
Of these 80 participants, 42% had severe ED (IIEF 5-7), making this the largest 
group at presentation. This is in contrast to the findings of the Massachusett
Male Aging Study where only 9,6% of the 52% of men who had ED prese
with complete ED, while 25,2% had moderate ED and 17,2% had minimal ED 
(Feldman et al 1994). LH, testosterone, age, smoking history, ED duration, HDL 
and waist to hip ratio showed strong correlation with IIEF score althoug
reached significance. The average IIEF score among the 39 participants with M
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is 9,2 and this is not worse than the score of 9,4 among those without MS. 
current study, it can be concluded that participants with MS do not have
severe ED than those without MS. This is contrary to the findings of D
In the 
 more 
emir et al 
006. 
-
ould be <4,5 mmol/l.  
ceride of 1,5 mmol/l falls within the recommended 
h is a 
2
 
4.5 The fasting lipogram  
Hypercholesterolaemia is a well known risk factor for cardiovascular events and 
men with ED may well have dyslipidaemias (Seftel et al 2004).The mean total 
fasting cholesterol is 4,5 mmol/l. The recommended cholesterol limits vary 
between institutions and generally depend on other risk factors. Category one 
risk or high risk individuals should keep their fasting cholesterol below 4,5 
mmol/l. This includes people with established atherosclerosis, coronary artery 
disease, cerebrovascular disease, peripheral vascular disease and type two 
diabetes mellitus.  The average fasting cholesterol in the Other group is well 
above this level and since 18 of the 24(75%) participants in this group had a co
morbid disease increasing their cardiac risk profile, the target cholesterol for 
them w
 
The mean total fasting trigly
range of <1,7 mmol/ l (IDF criteria). However once again the Other group had a 
mean triglyceride level above the recommended range with a value of 1,8 
mmol/l. Eleven participants(46%) in this group had raised triglycerides whic
much higher percentage than in the Black (n=13;21%) and White (n=2;13%) 
group. Since triglyceride levels fluctuate with food intake, it is important to 
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consider only fasting levels, for these one has to rely on participants being 
truthful regarding their recent intake. 
 
Fasting HDL forms an important component in the diagnosis of MS, less than 
1,03 mmol/l being a criterion. All group means and the total mean HDL are 
above this level in the current study. Only 14(23%) Black and 3(20%) White 
articipants had HDL below the critical level, but once again the Other group had 
wn to 
er 
mol/l. 
ase 
t al 
or MS 
iagnosis.  
p
the highest percentage of participants with low HDL, totalling 12(50%). 
 
Although LDL is not included in the definition of MS, it has clearly been sho
be a risk factor for cardiovascular disease (Eckel 2005, Kim 2000). Individuals at 
high risk (category one) should aim for fasting LDL levels <2,5 mmol/l. The 
sample mean for LDL is above this level at 2,6 mmol/l. Once again the Oth
group had the worst results with a mean of 3,1 mmol/l with only 7(29%) 
participants having LDL levels < 2,5 m
 
4.6 Indices of glucose metabolism 
Disorders of glucose metabolism carry significant risk for cardiovascular dise
and ED, the main one in the elderly being type two diabetes mellitus (Seftel e
2004). Nineteen participants had been diagnosed with type two diabetes mellitus 
prior to participation in the study which is on its own a positive criterion f
d
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The other criterion is a fasting plasma glucose ≥5,6 mmol/l. Mean fasting pla
glucose levels are 5,9 with the Other group having a significantly higher level, 
mmol/l (p=0,05). Accurate indices of glucose metabolism are highly depe
on a state of fasting and once again study pa
sma 
7,2 
ndent 
rticipants were requested to fast 
nd be truthful about their intake. 
er 
 to be expected as this group does have highest prevalence of 
iabetes mellitus. 
e, however considered on their own insulin 
vels are notoriously inaccurate. The highest levels are found in the Other group 
ore 
ce is 
ts with normal weight should have a score of 1. Once again 
a
 
Glycated haemoglobin levels can be used as an indicator of glucose control over 
the preceding three month period. Non-diabetic participants are expected to 
have levels < 6% while diabetic sufferers can aim for a target value < 7%. The 
mean total HbA1c is 6,5% with the Other group having a value of 7,2%. Howev
this result is
d
 
Serum insulin levels can vary markedly with oral intake and the presence of 
insulin resistance or diabetes mellitus. The reference range for insulin given by 
National Health Laboratory Services is 8,9-28,4 mU/l. Higher levels would 
appear to suggest insulin resistanc
le
(16,7 mU/l; p=0,049) which would appear to correlate with the higher prevalence 
of diabetes. To improve the predictive capabilities of insulin, the HOMA-IR sc
was computed with the following formula: fasting plasma glucose (mmol/l) x 
fasting plasma insulin (mU/l) / 22,5 (Matthews et al 1985). Higher values indicate 
insulin resistance and the present cut-off for the diagnosis of insulin resistan
2,5. Normal subjec
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the significant differences between the groups as shown by ANOVA was due to 
a 
 
vels. 
e 
 
sity, 
have 
the Other group having a score of 5,5 (p=0,02). 
 
4.7 Endocrine parameters 
A male hormone profile is usually performed as part of a diagnostic work-up of 
man with ED. It stands to reason that men with hypogonadism may experience 
weak or absent erections. There is no standard value for low testosterone, and 
laboratory reference ranges are usually provided. The NHLS range is 8,4-28,7 
nmol/l. Follicle Stimulating or Luteinising Hormone levels accompany 
testosterone and give an indication of testicular function. Reference ranges are 
given in section 3.7. Hypogonadism was present in 37 participants, while 
17(44%) men with MS were also hypogonadal. The significantly raised LH in the
White group is likely due to an outlying value of 44 IU/l in one participant, and all 
groups had normal mean LH and testosterone le
 
4.8 The metabolic syndrom
The real prevalence of MS worldwide is difficult to ascertain due to the various 
definitions which have been used in the past. Data from developed countries 
would be difficult to extrapolate to South Africa. Prevalence studies from South 
Africa have been infrequent and rarely focused on Men’s Health issues such as
ED. Prevalence of MS is certainly showing an upward trend due to obe
inactivity and urbanisation. It is estimated that half of South Africans may be 
overweight or obese and that as many as 1 in 4 South African adults may 
MS. Worldwide prevalence statistics for MS appear to be in the region of 25% of 
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adults. It may be assumed that certain populations or groups of patients would 
have a higher prevalence of MS, for example diabetics or patients with coronary 
eart disease. Since these are well known risk factors for ED as well, it may be 
would have a higher prevalence of MS. The 39% 
ias 
at 
f 
that 
esses 
 
h
extrapolated that men with ED 
prevalence of MS in the current study may be explained by the multitude of co-
morbid illnesses the participants presented with, as hypertension, dyslipidaem
and diabetes are all associated with MS. The Black participants showed the 
lowest prevalence of MS at 33%. Historically, South African Black people had a 
lower incidence of cardiac events due to less sedentary liestyles and lower f
diets than their white countrymen. With urbanisation and exposure to 
‘Westernised’ diets this seems to be changing as more Black people are 
presenting with lifestyle diseases. The 40% prevalence of MS among White 
participants is also higher than would be expected from the general public, but 
this figure is more understandable considering the more sedentary lifestyles and 
high fat diets that are more prevalent in this population group. Cardiovascular 
disease is usually cited as the most common cause of death in Caucasian males 
in South Africa. The highest prevalence of MS is found in the group composed o
males of Asian, Chinese and Coloured descent where 54% of participants were 
diagnosed with MS. Although the group numbers are small, the results show 
if men from these population groups present with ED, they are more likely to 
have MS than not. 
 
 Of interest, 8(21%) participants with MS had no prior history of chronic illn
or chronic medications suggesting that MS can be completely asymptomatic.
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Men presenting with ED may represent an ideal patient group to screen for MS,
and therefore for cardiovascular disease, especially for those men within the 
asymptomatic period. 
 
4.9  Limitations and recommendations 
Modern day prevalence studies in developed countries usually involve thousands
of participants. The three largest and most relevant studies conducted in Men’s 
Health recently, namely Framingham, MALES and MMAS referenced in the 
literature review, en
 
 
rolled thousands of men. It is difficult making comparisons 
ith the current study due to the much smaller sample size, particularly when the 
re 
e a 
ulation may have access to the study. 
s not allow assessment of the 
t 
w
100 participants are further subdivided into three groups. The smaller the sample 
is, the more likely it is that results may be influenced by chance. The tertiary ca
Centre is not the ideal place to do epidemiological or prevalence studies of such 
large magnitude, and future studies could perhaps be community-based wher
significantly larger pop
 
 Limiting participants to those with ED doe
prevalence of ED in a South African setting. This could be done by screening 
men in the community for ED symptoms. The IIEF proved to be a valuable, 
standardised, cross-cultural tool which was easily administered in the curren
study. Reliance on participant honesty when filling out the questionnaire is 
always a consideration when administering a functional score tool. 
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A comprehensive cardiovascular assessment was not performed in the current 
study, for example an electrocardiogram or angiogram, to detect symptomatic or 
asymptomatic coronary artery disease. It would be interesting to know the 
revalence of cardiovascular disease in the current sample as some participants 
he 
p
had been suffering from ED for several years, this was however beyond t
scope of the current study.   
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CHAPTER FIVE 
ONCLUSIONS 
he metabolic syndrome is a combination of medical disorders that increase the 
sks of cardiovascular disease and diabetes mellitus. It affects a great number of 
eople, with prevalence increasing with age. The pathophysiology is complex 
nd only partially understood.  Controversy exists as to whether MS is a real 
yndrome as the aetiology has not been well defined. The fact remains that the 
lustering of components of MS are very prominent among those people at risk 
r ischaemic heart disease or frank diabetes. These components are also the 
sk factors for erectile dysfunction, therefore it has been suggested that 
ents for asymptomatic coronary artery disease may be cost 
 with established CAD experienced ED symptoms on average 
o to three years before the onset of coronary symptoms, suggesting that ED 
 a 
rly not 
s 
 
C
 
T
ri
p
a
s
c
fo
ri
screening ED pati
effective. Patients
tw
may be a warning sign or an opportunity for early intervention. Considering the 
impact that cardiovascular disease has on morbidity, mortality and the health 
budget, screening for asymptomatic disease and primary prevention should be
priority. Aggressive lifestyle changes and possibly medications could be 
implemented to prevent the progression from asymptomatic MS to life-
threatening cardiovascular and cerebrovascular disease. 
 
The prevalence of MS in South Africa has not been well studied, particula
in a subset of males with ED. The current study was designed to determine thi
prevalence as well as the severity of ED and other risk factors contributing to this
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common disorder with a significant impact on quality of life. The prevalence of 
MS in one hundred men with ED was 39%, with the highest percentages in a 
mixed group of Asian, Coloured and Chinese origin. The average duration of E
was 3,8 years with an average IIEF-5 score of 9 (moderate ED). MS did not 
affect ED severity as per IIEF-5 score. Of interest, 8 participants with MS
prior history of chronic illnesses, other than ED, or chronic medications 
suggesting that MS can be completely asymptomatic. Men
D 
 had no 
 presenting with ED 
ay represent an ideal patient group to screen for MS, and therefore for 
 
m
cardiovascular disease, especially for those men within the asymptomatic period.
ED is probably the most sensitive barometer of men’s health worldwide, and 
several new insights will allow us to see ED as part of a broader health risk and 
not as an isolated dysfunction. 
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 DEPARTMENT OF SURGERY  
UNIVERSITY OF THE WITWATERSRAND 
DIVISION OF UROLOGY 
           JOHANNESBURG HOSPITAL 
_______________________________________________________ 
 
Study title: The prevalence of the metabolic syndrome in men 
presenting with erectile dysfunction in South Africa 
PARTICIPANT INFORMATION SHEET
 
 
 
Hello. My name is Dr BR Wood; I am a Urology Registrar in the Department of 
 Joha
suffering from erectile dysfunction and the risk factors involved, in particular the 
metabolic syndrome. The larities in 
cholesterol, blood glucose, blood pressure and body weight. The study will take 
place at the Johanne e degree (MMed). 
would like to invite you to consider participation in the study. Participation is 
benefits. You may discontinue participation at any time without giving a reason. 
 
Urology at the nnesburg Hospital. I will be conducting a study on men 
metabolic syndrome consists of several irregu
sburg Hospital as part of a post-graduat
 
I 
entirely voluntary and refusal to participate will involve no penalty or loss of 
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Should you agree to participate, you will be asked to sign the accompanying 
consent form, and you
 
 
ke to 
 
dy 
ing 
 brief questionnaire 
onsisting of five questions regarding your sexual health will be filled in. Should 
al 
ecorded: height, weight, blood pressure and waist 
ircumference. 
 
 will be given a copy to take home. 
Before you agree to participate, I would like you to read through this information
leaflet about the study. This leaflet will help you decide whether you would li
participate in the study. It may contain words that you do not understand. Please
ask me to explain any information. You may take home an unsigned copy of this 
leaflet and consent form to think about it or to discuss with your family before 
making your decision. 
 
The study will take place at the Johannesburg Hospital Men’s Sexual 
Dysfunction Clinic. Approximately one hundred participants who meet the stu
criteria will be enrolled in the study. The total assessment will be completed in 
the first clinic visit and will take roughly thirty minutes. A medical history includ
medications, illnesses and smoking habits will be taken. A
c
you participate, it is very important that you be truthful during the history and 
questionnaire so as not to jeopardise the results. 
 
An examination, which is the routine examination done at the clinic, will then be 
performed whether or not you are involved in the study. The following addition
measurements will be r
c
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Certain blood tests will be performed as part of the study. Once again,
blood tests are done routinely for all clinic attendees as part of standard clinical 
care,  regardless of whether you are enrolled in the study or not. Approximately
fifteen millilitres (three teaspoons) of blood will be drawn by experienced clinic 
staff using a sterile technique. You may experience slight discomfort during the
procedure as well as bleeding from the puncture site, bruising and a feeling of 
faintness. The following tests will be done on your blood samples: fasting 
lipogram (cholesterol and fats), fasting blood gluco
 these 
 
 
se and hormone profiles 
estosterone and insulin). 
 
 do 
rate history or do not follow the study guidelines, you may be 
ithdrawn at any time. You will not be paid money to participate in the study as 
l 
 of 
t you 
 you to the hospital. Should you be newly diagnosed 
ith any abnormality we will refer you to the relevant clinics at the Johannesburg 
(t
 
Your participation in this study will contribute to medical knowledge that may help
other patients, however, you may not benefit directly from this study. If you
not give an accu
w
no extra cost will be incurred by you. 
 
 
All your details will be treated with complete confidentiality, and your identity wil
not be made known. Data from the study will be pooled, analysed and may be 
presented at scientific meetings and in scientific journals. At no stage will it be 
possible to identify you as a participant. You will be informed of any finding
importance to your health at your next clinic visit, alternatively we will contac
with the details provided by
w
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Hospital for example diabetic, hypertension or lipid clinic. This clinical study 
protocol has been submitted to The University of Witwatersrand Human 
Research Ethics Committee and written approval has been granted by that 
Committee, approval has also been sought from the Hospital Superintendent. If 
you would like more information, please contact me at the clinic on (011) 488 
4463. 
 
 
 
 
Dr BR Wood 
Department of Urology 
University of the Witwatersrand and Johannesburg Hospital 
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 DEPARTMENT OF SURGERY  
UNIVERSITY OF THE WITWATERSRAND 
DIVISION OF UROLOGY 
JOHANNESBURG HOSPITAL   
_______________________________________________________ 
 
Study title: The prevalence of the metabolic syndrome in men 
presenting with erectile dysfunction in South Africa 
 
PARTICIPANT CONSENT FORM
 
 
hereby confirm that I have been informed by the study doctor, Dr BR Wood 
re, c
I have also received, read and understood the participant information sheet 
regarding the study. 
I am aware that the results of the s ils regarding sex, 
age, date of birth and dia ssed into a report. 
e  study. 
re 
 
I 
about the natu onduct, benefits and risks of the abovementioned study. 
tudy including personal deta
gnosis will be anonymously proce
I may at any stage, without prejudice, withdraw my consent and participation in 
th
I have had sufficient opportunity to ask questions and of my own free will decla
myself prepared to participate in the study. 
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PARTICIPANT 
 
           
                    
Print name                              Signature                              Date and time 
 
I Dr BR Wood, herewith confirm that the above participant has been fully 
informed about the nature, conduct and risks of he above study. 
 
STUDY DOCTOR 
 
                                                
 
  
                       Signature                            Date and time Print Name        
 
WITNESS/TRANSLATOR 
 
                                                                   
 
Print name                                 Signature                           Date and time 
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IIEF-5 QUESTIONNAIRE 
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The IIEF-5 Questionnaire 
Please tick appropriate box 
Over the past 6 months: 
1. How do you rate 
your confidence 
that you could get 
and keep an 
erection?  1 2 3
 
 
4 
Very 
High 
 
5
Very low 
 
 
Low 
 
 
Moderate 
 
 
High
 
 
  
2. When you had 
erections with 
sexual stimulation, 
how often were 
your erections 
hard enough for 
penetration? 
Almost 
never / 
never 
 
 
 
 
1
A few times 
(much less 
than half the 
time) 
 
 
2
Sometimes 
(about half 
the time) 
 
 
 
3
Most times 
(much 
more than 
half the 
time) 
 
4 
Almost 
always / 
always 
 
 
 
5
 
3. During sexual 
intercourse, how 
often were you 
able to maintain 
your erection after 
you had 
penetrated your 
rtner? 
Almost 
never / 
never 
 
 
 
 
 
1
A few times 
(much less 
than half the 
time) 
 
 
 
2
Sometimes 
(about half 
the time) 
 
 
 
 
3
Most times 
(much 
more than 
half the 
time) 
 
 
4 
Almost 
always / 
always 
 
 
 
 
5pa
 
4. During sexual Extremely 
ult 
 
Very difficult 
 
 
 
 
2
Difficult 
 
 
 
 
3
Slightly 
difficult 
 
 
 
 
4
Not 
difficult 
 
 
 
 
5
intercourse, how diffic
difficult was it to  
maintain your  
erection to 
completion of 
intercourse? 
 
1
  
 
5. When you 
tempted sexual 
Almost 
never / 
                1
A few times
(much less 
2
Sometimes
(about half 
3
Most time
(much 
 
4 
Almost 
always / 
5
s   
at
the time) 
 
 
 
than half the 
time) 
 
 
intercourse, how 
often was it 
satisfactory for 
you? 
never 
 
 
 
  
more than 
half the
time) 
 
always 
 
 
 
 
IIEF, International Index of Erectile Function, Adapted from Rosen RC et al(1999) 
nal tence R 6) t  International Jour
 
of  Impo esearch 11( .                  S udy number:
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DEPARTMENT OF SURGERY  
SRAND 
DIVISION OF UROLOGY 
JOHANNESBURG HOSPITAL   
____________________________ __________________________ 
Study title: The prevalence of the metabolic syndrome in men 
presenting with erectile dysfunction in South Africa 
     
                                         DATA COLLECTION SHEET 
 
                    UNIVERSITY OF THE WITWATER
_
 Study number: 
 
 Age: 
 
 Race: 
 
 Occupation: 
 
 Smoking History
 
: 
 Medical illnesses:
 
 
 Current medications: 
 
 Duration of ED: 
 
 IIEF-5 score: 
 
 Waist circumference(cm): 
 
 Hip circumference(cm): 
 
 Weight(kg): 
 
 Height(cm): 
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 BMI: 
 
 Blood pressure(mmHg): 
 
 Total fasting cholesterol(mmol/l): 
 
 Fasting triglycerides(mmol/l): 
 
 Fasting HDL(mmol/l): 
 
 Fasting LDL(mmol/l): 
 
 Fasting glucose(mmol/l): 
 
 Fasting serum insulin(mU/l): 
 
 HbA1c(%): 
 
 Testosterone(nmol/l): 
 
 LH(IU/l): 
 
 FSH(IU/l): 
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APPENDIX 6 
 
HOSPITAL SUPERINTENDENT PERMISSION 
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APPENDIX 7 
 
IIEF QUESTIONNAIRE 
 
 
 
 
 
 
 
 
 
 
The IIEF Questionnaire 
Please tick appropriate box 
Over the past 4 weeks: 
 
unction, Adapted from Rosen RC et al(1997) 
Urology 49.                   
IIEF, International Index of Erectile F
 73
